Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

572 - Herbal product and dietary supplement intake among patients at the Philippine General Hospital (PGH) medical oncology clinic: a cross-sectional survey.

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Rich Ericson King

Citation

Annals of Oncology (2018) 29 (suppl_9): ix129-ix138. 10.1093/annonc/mdy444

Authors

R.E. King1, D.L. Sacdalan1, R.R. Angeles2

Author affiliations

  • 1 Medical Oncology, Philippine General Hospital, 1000 - Manila/PH
  • 2 Department Of Medicine, Philippine General Hospital, 1000 - Manila/PH
More

Resources

Abstract 572

Background

The use of herbal products and dietary supplements (HDS) seem to be common among Filipinos. Among patients living with cancer, this is an important concern due to potential adverse effects and harmful interactions with conventional systemic therapy. Unfortunately, data is lacking regarding the prevalence and patterns of HDS use in this population.

Methods

380 patients with cancer on follow-up at the PGH Medical Oncology outpatient clinic were surveyed regarding their status and patterns of HDS intake. Information sought included timing of initation, frequency of use, monitoring, sources of information, expenditure, and intended purpose. Data on doctor-patient discussions were also obtained. HDS intake was correlated with demographic data using crude odds ratio. Data analysis was done using Microsoft Excel.

Results

Among 380 respondents, 88.95% reported ever using HDS, with 178 (46.84%) having used in the past month. The demographic characteristics of HDS users did not differ significantly from non-users. Among 338 ever users, majority (63.02%) initiated HDS only after cancer diagnosis; 62.72% reported almost daily use. Mean reported HDS expenditure was PhP 2,463.78 monthly. Users were largely unmonitored (76.29%), and 42.31% reported to have used HDS while on systemic therapy. Eighty-five patients (25.15%) reported to have previously delayed conventional treatment in favor of HDS. Only 30.53% of patients ever had discussions on HDS in the clinic, of which only 24 (20.69% of discussions) were doctor-initiated.

Conclusions

HDS use is prevalent among Filipinos with cancer and can potentially lead to delays and interference with systemic treatment. The outpatient consult is a golden opportunity to properly educate patients regarding HDS use.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Philippine General Hospital - Department of Medicine.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.